Piper sees ‘attractive buying opportunity’ into NewAmsterdam data

Piper Sandler believes NewAmsterdam Pharma is a “key name to own” in 2024 with its Q4 “stock-moving event and low clinical risk.” Now is an “attractive buying opportunity” into the BROADWAY data, which is likely to come in November, the analyst tells investors in a research note. The firm says BROADWAY “appears de-risked” and keeps an Overweight rating on NewAmsterdam with a $37 price target.